Pharmaceutical Technology

DECEMBER 8, 2022

In December last year, the first centre in Japan received authorisation to administer the therapy, while six regional hospitals are currently approved to offer this treatment. Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. By Cytiva Thematic.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

The Pharma Data

JANUARY 17, 2021

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease. There is significant unmet medical need for a sustained therapy to treat eye diseases. MUNICH, Germany, Jan.

Gene Therapy 52

Gene Therapy Gene Research Protein 52

Pharmaceutical Technology

JULY 6, 2022

These involve mRNA molecule engineering, including sequence modifications to enhance stability and boost protein expression, and mRNA vaccine formulations appropriate for SARS CoV-2 vaccines. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccination 182

Vaccination Vaccine Gene Therapy Engineer 182

Pharmaceutical Technology

JUNE 29, 2022

Specialty enzymes are proteins that can act as very specific biocatalysts to accelerate reactions and produce the desired target molecule in pharmaceuticals,” explains Kristoffer Laursen, Head of R&D at Novo Nordisk Pharmatech. In the evolving biotechnology industry, enzymes are important process aids.

Drugs 295

Drugs Gene Therapy Manufacturing Production 295

Drug Discovery World

NOVEMBER 1, 2022

Researchers say they have successfully used a cell’s natural process for making proteins to ‘slide’ genetic instructions into a cell and produce critical proteins missing from those cells. . Therapies that don’t precisely target diseased cells can have unintended effects in other healthy cells.” . Initial success in the lab.

Gene Expression 52

Gene Expression Gene Packaging Packaging 52

pharmaphorum

JANUARY 29, 2021

Since that discovery, a flurry of gene-editing focused biopharma companies have launched – including Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences and Mammoth Biosciences – and the first drug therapies based on the technology are now in human testing for diseases like cancer. Macrae explains. “So

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. One strategy proposed the use of synthetic mRNA or modified mRNA analogs, which can enhance the stability and protein expression of mRNA.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

Drug Discovery World

OCTOBER 20, 2023

Its proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis. Through the purchase, Thermo Fisher will also gain a library of more than 5,300 validated protein biomarker targets. Olink specialises in solutions for proteomics discovery and development.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

Pharmaceutical Technology

JUNE 21, 2023

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). Hemgenix is the first and only gene therapy approved for haemophilia B. per dose, it is the most expensive single-use gene therapy in the US.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

APRIL 3, 2023

As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

The Pharma Data

DECEMBER 31, 2020

Taysha Gene Therapies – Texas-based Taysha Gene Therapies bolstered its leadership team with the appointments of Greg Gara as senior vice president of Manufacturing and Kimberly Lee as senior vice president of Corporate Communications and Investor Relations. He is currently the CEO of BlockchainK2 Corp.,

Gene Therapy 52

Gene Therapy Engineer Gene Research Analyst 52

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. The Promise of Gene and Cell Therapies: Beyond monoclonal antibodies and protein-based biologics, the field of biotechnology is rapidly advancing towards the development of gene and cell therapies.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

pharmaphorum

DECEMBER 1, 2022

Learn how to implement 3D Cell Culture techniques for antibody and cell and gene therapy discovery process. Academia – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering. Featured Speakers Include: Stefan Przyborski, Professor Cell Technology, Durham University.

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

Drug Discovery World

MAY 7, 2024

However, despite these advancements in process optimisation and cell culture engineering, there remain areas that we need to improve. RA: What are some of the current limitations for producing mAbs? DC: For the past few decades, there have been many advancements in the biotechnology space.

Antibody 59

Antibody Production Manufacturing Engineer 59

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. This candidate, derived from a person’s own genetically modified cells, aims to restore the Gag-specific CD4+ T cell response in those receiving antiretroviral therapy.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Drug Discovery World

JANUARY 9, 2023

How to accelerate the CAR research pipeline with protein engineering tools. The post Improving cell therapies with high-throughput CAR libraries appeared first on Drug Discovery World (DDW). Rapid screening for functional and therapeutically effective TCRs. Discovery of targeting domains for CART-T constructs.

Engineer 52

Engineer Protein Research Drugs 52

Drug Discovery World

JANUARY 9, 2023

How to accelerate the CAR research pipeline with protein engineering tools. The post Watch now: Improve cell therapies with high-throughput CAR libraries appeared first on Drug Discovery World (DDW). Rapid screening for functional and therapeutically effective TCRs. Discovery of targeting domains for CART-T constructs.

Engineer 52

Engineer Protein Research Drugs 52

Scienmag

DECEMBER 7, 2020

Penn Medicine study shows how editing out CD5 on CAR T cells may improve the therapy and expand its use PHILADELPHIA– Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells’ ability to eliminate blood cancers, according to new preclinical data from […]. (..)

Engineer 40

Engineer Protein Medicine Gene Therapy 40

pharmaphorum

OCTOBER 13, 2022

Bayer’s quest to revamp its drug discovery engine continues apace, with the company’s recently acquired Vividion subsidiary forging an alliance with Tavros Therapeutics, aimed at finding new drug targets and biomarkers in oncology. Bayer bought Vividion for $1.5

Gene Therapy 63

Gene Therapy Genome Genomics Drugs 63

pharmaphorum

JANUARY 3, 2023

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for treatment of adult males with moderately severe to severe haemophilia B.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

XTalks

OCTOBER 20, 2023

Hereditary ATTR (ATTRv) amyloidosis occurs due to mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a tendency to misfold. Intellia’s therapy is designed to be a one-time treatment for ATTR amyloidosis.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

pharmaphorum

JULY 11, 2022

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the International Society on Thrombosis and Haemostasis (ISTH) congress over the weekend.

Engineer 52

Engineer Sales Gene Therapy Drugs 52

XTalks

AUGUST 19, 2022

Bluebird bio’s gene therapy Zynteglo (betibeglogene autotemcel, beti-cel) has been awarded a much anticipated approval from the US Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with beta thalassemia who need regular blood transfusions. Bluebird has a total of three gene therapies in its pipeline.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

Drug Discovery World

AUGUST 5, 2022

Evonetix is reimaging biology by developing a different approach to gene synthesis. After some calculations on a whiteboard, I realised that it is controllable and within the laws of physics – it was just an engineering challenge. He holds a PhD and MEng in Electronic Engineering, both from Loughborough University.

DNA 52

DNA Engineer Gene Sequencing Gene 52

The Pharma Data

MARCH 16, 2022

The research scientist at the Max Planck Institute for Medical Research received the award in recognition of his ground-breaking work in establishing various approaches to protein labeling in living cells that have enabled far-reaching advances in chemical and cell biology. Protein labeling (e.g.

Protein 52

Protein Scientist Gene Development 52

Drug Discovery World

MARCH 13, 2023

The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. link] “COVID-19 and cell and gene therapy: How to keep innovation on track.”

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

The Pharma Data

JANUARY 7, 2021

To meet that goal, Sanofi is investing in areas like synthetic biology and cell and gene therapy. He also noted innovations are occurring with protein degraders, antibody conjugates, nanobodies and multi-specific antibodies, specifically bi- and tri-specific. billion acquisition of Synthorx. billion acquisition of Synthorx.

Protein 52

Protein Antibody Genetics Gene Therapy 52

The Pharma Data

JANUARY 10, 2021

FBX-101 is a first-in-human AAV gene therapy. Krabbe disease is a rare and fatal pediatric leukodystrophy caused by mutations in the galactosylceramidase (GALC) gene. INZ-701 is a soluble, recombinant protein containing the extracellular domain of native human ENPP1 fused to the Fc domain of the immunoglobulin IgG1.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

Drug Discovery World

OCTOBER 16, 2023

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. billion in funding. We also recently opened the Scientific Centre of Excellence for Genomic Insight at our Cambridge site.”

Drugs 75

Drugs Life Science Gene Therapy Genome 75

XTalks

FEBRUARY 27, 2024

TIL vs CAR T-Cell Therapies While CAR T-cell therapies involve inserting a CAR engineered to target a specific cancer cell protein into a patient’s T cells, TIL-based T-cell therapies like Amtagvi involve separating TILs from a patient’s tumor (in autologous therapies) and expanding them ex vivo.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

The Pharma Data

JANUARY 24, 2021

Researchers at Faze are harnessing the power of biomolecular condensates, membrane-less clusters of molecules that dynamically organize to perform a wide array of cell functions, to advance potential breakthrough therapies. He earned his B.Sc. in applied biochemistry from the University of Salford in Manchester, England and his Ph.D.

Medicine 52

Medicine Pharma Companies Gene Therapy Development 52

XTalks

MAY 9, 2024

In turn, this advent in AI and machine learning has the potential to lead to the discovery and development of more effective therapies. What factors do you attribute to the company’s success in the discovery and development of differentiated antibody therapeutics?

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

The Pharma Data

OCTOBER 27, 2020

Former Sarepta Therapeutics executive Bo Cumbo left to launch his new gene therapy company, AavantiBio, with a $107 million Series A. AavantiBio’s strategic partnership with University of Florida’s Powell Gene Therapy Center provide their foundational research in rare genetic disorders. AavantiBio .

Gene 52

Gene Gene Therapy Medicine Genetics 52

Scienmag

FEBRUARY 21, 2021

‘Exploring one of the biggest challenges facing genomics today – understanding genetic variants’ SEATTLE (February 22, 2021) – Global experts performing leading edge research in precision medicine, functional genomics, protein science, and variant interpretation and prediction will share their expertise and insights April 5-7 (..)

Genome 40

Genome Genomics Genetics Protein 40

Roots Analysis

AUGUST 31, 2023

Further, the expression of any gene is dependent on the rate at which it is transcribed into mRNA and translated into proteins. There are various regulatory proteins or transcription factors that are responsible for affecting the transcription rate.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52